The ICU Trial That Should Embarrass Every Sponsor Hiding Behind “Ethical Complexity”
A JAMA RCT on ICU restraint strategies just proved rigorous trial design works even in critically ill patients —...
Ascentage Pharma Presents Promising Cancer Research at AACR
Across four AACR posters, Ascentage reported preclinical synergy signals spanning hematologic and solid tumors: olverembatinib enhanced chemotherapy activity in...
Sutro’s Emerging ADC Pipeline Shows Promising Preclinical Data
In preclinical studies presented at AACR, Sutro’s tissue factor–targeted ADC STRO-004 delivered broad antitumor control across multiple TF-expressing solid...
ALXN1840’s Triumph: Neurologic Hope in Wilson Disease
Clinically meaningful neurologic worsening at Week 48 occurred in 25% of patients on standard of care versus 9% on...
Xenon Presents Azetukalner Phase 3 Seizure Study Results
Azetukalner cut monthly focal-onset seizure frequency by a median 53.2% at 25 mg and 34.5% at 15 mg over...
New Zoldonrasib Clinical Data for KRAS G12D Lung Cancer
In a Phase 1 dose-expansion cohort of previously treated KRAS G12D non-small cell lung cancersmall cell lung cancer, zoldonrasib...
meiragtx Announces Positive 3-Year Xerostomia Trial Data
Three-year follow-up from MeiraGTx’s Phase 1 AQUAx study showed sustained, clinically meaningful improvements in patient-reported xerostomia symptoms and persistent...
Remedy Plan Therapeutics Announces AACR 2026 Presentations
Remedy Plan Therapeutics will bring a broad slate of AACR presentations centered on RPT1G, its “hyperbolic” NAMPT inhibitor now...
Bioxodes Shares Pivotal Trial Design for BIOX-101 in ICH
Bioxodes is moving BIOX-101 into an adaptive Phase 2b/3 study in intracerebral hemorrhage with functional outcome (mRS) as the...
AIM Plans Pivotal Phase 3 Trial for Pancreatic Cancer
In late-stage pancreatic ductal adenocarcinoma, rintatolimod (Ampligen) has generated early clinical signals across multiple settings: a Dutch named-patient program...